Sarcoidosis is a multisystem disease which may present with non-specific symptoms or symptoms related to organ-specific involvement.
Non-specific symptoms include fever, malaise, fatigue and weight loss.
Pulmonary involvement is seen in >90% of sarcoidosis patients.

Follow Up

General Surveillance Principles

  • Sarcoidosis patients should be monitored regularly
  • Monitoring should include a review of symptoms, physical exam, CXR & lung function tests
    • Perform other tests as necessary based on organ involvement
  • Monitor & treat patients for complications of sarcoidosis & related conditions (eg aspergilloma, osteoporosis, hypercalcemia, hypercalciuria)
  • Patients who have undergone therapy should be monitored for 3 years after cessation of treatment
  • Intermittent monitoring (every 3-6 months) is recommended for patients on TNF-alpha inhibitor therapy

Monitoring Intervals Based on Disease Stage

Stage 1

  • Initially every 6 months then once a year if stable

Stage 2, 3, 4

  • Initially every 3-6 months; monitor indefinitely

Serious extrapulmonary involvement, regardless of radiographic stage

  • Monitor indefinitely
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
Stephen Padilla, 09 Jan 2018
Very elderly adults have the highest rate of invasive pneumococcal diseases, according to a recent study, suggesting that age influences manifestations of this illness.
Kathlin Ambrose, 16 Oct 2015
The label of asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) should not be used when diagnosing patients displaying symptoms of both diseases says an expert. 
Greg Town, 01 Sep 2014

The temperature of a person’s exhaled breath may be a simple, non-invasive diagnostic test for non-small cell lung cancer (NSCLC), according to a study, the results of which were presented at the recent European Respiratory Society (ERS) International Congress held in Munich, Germany.

Elvira Manzano, 28 Nov 2017
The addition of the long-acting muscarinic antagonist (LAMA) tiotropium to maintenance therapy improves FEV1* and FVC** in patients with asthma, with a greater impact on FVC in those with a more severe disease, a post-hoc analysis of data from five phase III trials have shown.